Oligospermia secondary to sirolimus

Publication date: Available online 18 November 2015 Source:Indian Journal of Transplantation Author(s): Syed Sajad Hussain, Samina Farhat, Imtiyaz Wani Sirolimus, one of the leading drugs of the mammalian target of rapamycin inhibitor (mTORi) family, is a promising immunosuppressive drug being used after solid organ transplantation. The introduction of sirolimus in renal transplantation has increased the repertoire of immunosuppressive protocols substantially. It has a different mode of action and a different side effect profile (i.e. lower nephrotoxicity, less hypertension and less neoplastic potential) than the calcineurin inhibitors, the other commonly used post transplant immunosuppressive drugs. Here we present a case report of a 40-year-old patient who presented with oligospermia after consuming the sirolimus for three years.
Source: Indian Journal of Transplantation - Category: Transplant Surgery Source Type: research